- Home
- NBN vs GERN Comparison
NBN vs GERN Comparison
Compare NBN & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBN
- GERN
- Stock Information
- Founded
- NBN 1872
- GERN 1990
- Country
- NBN United States
- GERN United States
- Employees
- NBN N/A
- GERN N/A
- Industry
- NBN Major Banks
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- NBN Finance
- GERN Health Care
- Exchange
- NBN Nasdaq
- GERN Nasdaq
- Market Cap
- NBN 853.5M
- GERN 823.0M
- IPO Year
- NBN N/A
- GERN 1996
- Fundamental
- Price
- NBN $109.01
- GERN $1.27
- Analyst Decision
- NBN Buy
- GERN Buy
- Analyst Count
- NBN 2
- GERN 8
- Target Price
- NBN $97.50
- GERN $3.71
- AVG Volume (30 Days)
- NBN 66.4K
- GERN 5.5M
- Earning Date
- NBN 10-28-2025
- GERN 11-06-2025
- Dividend Yield
- NBN 0.04%
- GERN N/A
- EPS Growth
- NBN 32.98
- GERN N/A
- EPS
- NBN 10.08
- GERN N/A
- Revenue
- NBN $204,086,000.00
- GERN $164,447,000.00
- Revenue This Year
- NBN $17.75
- GERN $175.15
- Revenue Next Year
- NBN $9.91
- GERN $56.61
- P/E Ratio
- NBN $10.78
- GERN N/A
- Revenue Growth
- NBN 33.67
- GERN 11877.20
- 52 Week Low
- NBN $68.89
- GERN $1.09
- 52 Week High
- NBN $112.22
- GERN $4.83
- Technical
- Relative Strength Index (RSI)
- NBN 57.91
- GERN 41.64
- Support Level
- NBN $107.94
- GERN $1.23
- Resistance Level
- NBN $111.50
- GERN $1.33
- Average True Range (ATR)
- NBN 2.37
- GERN 0.07
- MACD
- NBN -0.59
- GERN -0.02
- Stochastic Oscillator
- NBN 28.03
- GERN 13.79
About NBN Northeast Bank
Northeast Bank provides banking and financial services to individual and corporate customers in the US. The firm conducts its loan-related activities through two primary channels: the Community Banking Division, and the Small Business Administration (SBA) National Division. Its loan portfolio comprises residential mortgage loans; multi-family and other commercial real estate loans; commercial and industrial loans, consumer loans, and small business administration loans. The firm also provides telephone banking, online banking, mobile banking, and remote deposit capture services. The revenue of the company is derived primarily from interest and dividends from the bank.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.